Can an adult with eGFR < 30 mL/min/1.73 m² safely replace lisinopril with enalapril 5 mg?

Can You Use Enalapril 5mg in Lieu of Lisinopril in Severe CKD?

Yes, enalapril 5 mg can be used as a direct substitute for lisinopril in patients with eGFR < 30 mL/min/1.73 m², but the starting dose should be reduced to 2.5 mg daily and uptitrated cautiously with close monitoring of potassium and renal function within one week of initiation. 1, 2

ACE Inhibitor Equivalence and Interchangeability

Both enalapril and lisinopril are ACE inhibitors with identical mechanisms of action, similar side effect profiles, and equivalent nephroprotective benefits in chronic kidney disease. 1 The 2017 ACC/AHA Hypertension Guidelines list both agents as primary antihypertensive options without distinguishing between them in terms of efficacy or safety. 1

• Enalapril's usual dose range is 5–40 mg daily in 1 or 2 divided doses, while lisinopril's range is 10–40 mg once daily. 1
• Both drugs carry the same warnings: increased hyperkalemia risk in CKD, risk of acute renal failure with bilateral renal artery stenosis, contraindication in pregnancy, and prohibition against use with ARBs or direct renin inhibitors. 1

Critical Dosing Adjustments for eGFR < 30 mL/min/1.73 m²

For patients with eGFR 10–30 mL/min/1.73 m² (including your patient with eGFR < 30), both enalapril and lisinopril require dose reduction to ½ of the usual starting dose. 2

• Enalapril should be initiated at 2.5 mg daily (half of the standard 5 mg starting dose) in this population. 1
• Lisinopril should be initiated at 5 mg daily for hypertension or 2.5 mg for heart failure in patients with eGFR 10–30 mL/min/1.73 m². 2
• Maximum target dose after uptitration remains 40 mg daily for both agents, even in severe renal impairment. 2

Pharmacokinetic Considerations

Both drugs are renally excreted and accumulate in renal failure, but this does not preclude their use—it mandates dose adjustment. 3, 4, 5

• Lisinopril and enalaprilat (the active metabolite of enalapril) have extremely slow plasma clearance in chronic renal failure, with plasma concentrations declining very gradually between dialysis sessions. 3
• In patients with GFR < 30 mL/min, drug accumulation occurs but is clinically manageable with reduced starting doses and careful titration. 4, 5, 6

Mandatory Monitoring Protocol

KDOQI guidelines explicitly state that RAAS antagonists should NOT be routinely discontinued when eGFR falls below 30 mL/min/1.73 m² because nephroprotection is preserved. 2, 7

Initial Assessment (Within 1 Week)

• Check serum potassium and eGFR within 1 week of starting enalapril or after any dose change. 2, 7

Hold Criteria

Temporarily suspend enalapril if any of the following occur: 2

• Serum potassium > 5.5 mmol/L
• eGFR decline > 30% from baseline
• Clinical evidence of acute kidney injury
• Acute illness, dehydration, bowel preparation, major surgery, or IV contrast administration

Ongoing Monitoring

• Monitor potassium and eGFR monthly for the first 3 months, then every 3 months if stable. 2
• Discontinue or markedly reduce potassium supplements when initiating enalapril. 2
• Avoid concomitant nephrotoxic agents (NSAIDs, aminoglycosides). 2, 7

Practical Switching Algorithm

If the patient is currently stable on lisinopril:

1. Directly substitute enalapril 2.5 mg daily (equivalent to low-dose lisinopril in severe CKD). 1, 2
2. Check potassium and eGFR within 1 week. 2
3. If tolerated and blood pressure control is inadequate, uptitrate by 2.5 mg increments every 2–4 weeks. 2
4. Maximum dose is 40 mg daily, though most patients with eGFR < 30 require only 5–20 mg. 4, 5, 6

If initiating ACE inhibitor therapy de novo:

• Start enalapril at 2.5 mg daily. 1, 2
• Follow the same monitoring and titration protocol above.

Expected Renal Effects

A transient decline in GFR of 10–30% is expected and acceptable after initiating ACE inhibitors in patients with advanced CKD. 8, 4, 5, 6

• In a study of 31 patients with severe chronic nephropathy (median GFR 14 mL/min), enalapril caused a median GFR decline of 14% (range -44% to +10%), which was clinically acceptable in most patients. 8
• In multiple studies of lisinopril in patients with GFR ≤ 60 mL/min, mean GFR remained stable or improved slightly over 12 weeks to 1 year, with individual variability. 4, 5, 6
• Patients who experienced renal vasodilation (increased effective renal plasma flow) maintained stable GFR, while those without vasodilation had progressive decline—this underscores the importance of individualized monitoring. 6

Common Pitfalls to Avoid

• Do not start at the standard 5 mg dose of enalapril in patients with eGFR < 30 mL/min/1.73 m²; begin at 2.5 mg. 1, 2
• Do not discontinue ACE inhibitors solely because eGFR is < 30 mL/min/1.73 m²—nephroprotection persists at low GFR. 2, 7
• Do not continue potassium supplements without close monitoring; hyperkalemia risk is substantially elevated. 2
• Do not combine with ARBs, aldosterone antagonists (unless K+ < 5.0 and eGFR > 30), or NSAIDs. 1, 2, 7
• Hemodialysis removes both lisinopril and enalaprilat significantly (plasma clearance ~40 mL/min during dialysis), so post-dialysis dosing may be required. 3